- €155.90bn
- €202.32bn
- $62.58bn
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma
Brief: Pfizer’s TALZENNA Plus XTANDI FDA-Approved For Earlier-Stage Metastatic Prostate Cancer
Brief: US FDA Approves Talazoparib With Enzalutamide For Metastatic HRR-Mutated Prostate Cancer
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Focus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Eli Lilly hits record high as healthcare stocks rally
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Healthcare stocks rally as investors seek safety amid tech debt worries
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Enodia Therapeutics Announces Research Collaboration And License Agreement With Pfizer To Develop Sec61-Targeting Small Molecules
Factbox: Major drugmakers turn to China for licensing deals
Pfizer to cut around 330 jobs in Italy, unions say (updated)
Pharma lobby sues Trump administration over Medicare drug price cuts (updated)
Pfizer to cut around 330 jobs in Italy